Athira Pharma's Shift Towards ALS Drug Development After Alzheimer's Drug Failure
Wednesday, 18 September 2024, 05:14
Understanding Athira Pharma's Strategic Shift
Athira Pharma is now redirecting its focus to ALS drug development following the disappointing results of its Alzheimer’s medication, fostgonimeton. The company will invest in the advancement of ATH-1105, recognizing the critical need for effective treatments in the ALS community.
Challenges Faced in Alzheimer’s Drug Development
- The Alzheimer’s drug was unable to meet the primary endpoints outlined in the LIFT-AD trial.
- Athira's decision comes as part of a broader strategic plan to minimize costs.
- The workforce reduction by 70% will help the company save an estimated $13.4 million.
Future Directions in ALS Drug Development
With the new commitment to ALS, Athira aims to leverage its resources towards discovering and developing therapies that address this devastating disease. Stay tuned for updates on their progress.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.